#lung cancer

First-Line Immunotherapy Combo Slows Lung Cancer Progression

As the lung cancer community and the lung cancer movement grew, the awareness activities increased

Cancer Health will be reporting live from major cancer conference in Chicago (June 1-5).

Experts urge public health campaign to highlight the benefits of early detection.

The actress has joined forces with the American Lung Association to raise awareness about the disease.

Testing for multiple mutations at once is faster and less expensive.

“We’re doing well, but we can do even better by personalizing therapies,” said Roy Herbst, MD, PhD, of the Yale Cancer Center.

Declining rates are expected for Kaposi sarcoma, non–Hodgkin lymphoma, cervical and lung cancer and Hodgkin lymphoma, among others.

The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.

This is according to a meta-analysis of a dozen studies conducted in North America and Europe.

Immunotherapy plus targeted therapy and chemotherapy extended progression-free survival by up to four months.

BLU-667 shrinks thyroid and lung cancers with RET gene alterations.

First-line combination therapy lowered the risk of death by 51 percent.

Osimertinib led to improved progression-free survival in people with common EGFR mutations.

First-line immunotherapy combo improved progression-free survival in people with highly mutated lung tumors.

Immunotherapy improved survival in people with locally advanced or metastatic disease.

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.